Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04933916 · ClinicalTrials.gov registry record · Phase 1
Study of EMB-001 as a Potential Smoking Cessation Treatment
A Phase 1 study, sponsored by Embera NeuroTherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04933916 is a Phase 1 study that was terminated before completion, run by Embera NeuroTherapeutics. The registered enrollment target is 16 participants.
The verdict
NCT04933916, a Phase 1 study, was terminated before completion, sponsored by Embera NeuroTherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is an open-label study in up to 50 adult subjects to help smokers abstain from smoking during a 12-week trial period.
Interventions
- DRUG EMB-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04933916
The ClinicalTrials.gov registry entry for NCT04933916 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Embera NeuroTherapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EMB-001 is the first listed.
NCT04933916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04933916 about?
NCT04933916 is a clinical study titled "Study of EMB-001 as a Potential Smoking Cessation Treatment". EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is an open-label study in up to 50 adult subjects to help smokers abstain fr...
What is the current status of trial NCT04933916?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-06-10. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT04933916?
The interventions under investigation include: EMB-001 (DRUG).
Who is sponsoring clinical trial NCT04933916?
This trial is sponsored by Embera NeuroTherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.